An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

 
• By Jessica Merrill and Mandy Jackson
  
ReviewStamp_1200x675
Amarin's Vascepa will get a US FDA advisory committee review. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapeutic Category